Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

Esai in the Drug Discovery & Development Pharma 50

Eisai

Rank: 38

2021 Rank: 30

Tokyo, Japan
www.eisai.com

2021 Revenues ($USD) : $5,880,371,449
2021 Revenues (foreign currencies) : JP¥645,942,000,000
2021 R&D spend : $1,368,344,865.26
2021 Number of Employees : 11,237
Fiscal Year End : 3/31/2021
Leader : CEO Haruo Naito

A result of the merger of two labs in 1944, Esai focuses on developing drugs for oncology and neurology indications. The company has a global network of R&D facilities with 14 drug discovery centers globally, manufacturing sites and marketing subsidiaries. Key products include the anti-cancer medication Lenvima (lenvatinib), the chemotherapy Halaven (eribulin mesylate), the anticonvulsant Banzel (rufinamide), the anti-epileptic medicine Fycompa (perampanel) and the insomnia treatment Dayvigo (lemborexant). —BB

Eisai

[Eisai site in Europe. Image courtesy of Eisai.]

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50